Operating cash flow tracked net losses closely with OCF/NI ratios between 0.71 and 2.45, and with no dividends, buybacks, or acquisitions across the period, capital was fully directed toward clinical activity, leaving free cash flow at -$93.1M in 2026Q3 and -$226.3M in 2026Q2.
Viridian Therapeutics, Inc. (VRDN) cash flow statement — 14-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -341.5M | -276.39M | -232.32M | -184.17M | -93.84M | -54.58M | -29.78M | -36.06M | -26.84M | -28.17M | -7.23M | -6.9M | -2.21M | -1.17M | -6.22M |
| Operating CF Margin % | - | -390.11% | -76926.82% | -58652.87% | -5295.6% | -1842.09% | -2836.1% | -808.25% | -320.1% | -703.65% | -216.69% | -271.79% | -51.23% | -27.05% | -141.28% |
| Operating CF Growth % | -10.92% | -18.97% | -26.14% | -96.26% | -71.92% | -83.29% | 17.41% | -34.32% | 4.7% | -289.53% | -4.83% | -211.7% | -89.5% | 81.24% | - |
| Net Income | -453.58M | -342.6M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.7M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -5.62M |
| Depreciation & Amortization | 701K | 460K | 540K | 522K | 255K | 120K | 239K | 288K | 281K | 308K | 341K | 184K | 144K | 148.31K | 144.29K |
| Stock-Based Compensation | 59.59M | 44.3M | 42.15M | 67.17M | 19.77M | 14.46M | 3.65M | 3.97M | 3.68M | 2.41M | 2.11M | 3.02M | 4.3M | 0 | 7.96K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 56K | -432K | -416K | 0 | 868K | 0 | 177K | 0 | -1.64M |
| Other Non-Cash Items | 2.22M | -1.58M | -14.66M | -4.71M | 54K | 8.52M | 72.57M | 340K | 376K | 94K | -59K | 132K | 953K | 1.49M | 2.49M |
| Working Capital Changes | 49.56M | 23.03M | 9.6M | -9.43M | 15.96M | 1.72M | 4.43M | 1.65M | 1.94M | -4.47M | 2.18M | 1.1M | 105K | -649.45K | -1.61M |
| Change in Receivables | -29.78M | 0 | 102K | 0 | 349K | -451K | 99K | -84K | 1.43M | -1.44M | -130K | 694K | -271K | 201.59K | -369.58K |
| Change in Inventory | -85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -57.8M | -50.9M | 123K | -8K | 178K | -187.1K | 166.39K |
| Change in Payables | -766K | 6.56M | -73K | -12.04M | 11.52M | 1.66M | -426K | 525K | -335K | -101K | 2.03M | 633K | 383K | -279.73K | -1.29M |
| Cash from Investing | -468.98M | -37.56M | -228.65M | -94.25M | -115.13M | -74.29M | -50.48M | 28.23M | -29.91M | 1.03M | -3K | -95K | -274K | 5.68K | -119.43K |
| Capital Expenditures | -1.94M | -495K | -511K | -898K | -797K | -338K | -42K | -84K | -445K | -246K | -3K | -123K | -266K | -4.77K | -106.91K |
| CapEx % of Revenue | 7.37% | 0.7% | 169.21% | 285.99% | 44.98% | 11.41% | 4% | 1.88% | 5.31% | 6.15% | 0.09% | 4.85% | 6.16% | 0.11% | 2.43% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 29.37M | -28.31M | 0 | 1.28M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -10M | 0 | 0 | 0 | 0 | 79K | -3K | 28.31M | -29.46M | 1.28M | 0 | 28K | -8K | 10.45K | -12.52K |
| Cash from Financing | 815M | 426.74M | 457.74M | 225.67M | 322.24M | 125.28M | 101.31M | 70K | 41.92M | 52.47M | -257K | 12.71M | 7.4M | 1.26M | 5.81M |
| Debt Issued (Net) | 224.18M | 28.88M | 0 | 15M | 5M | 0 | -8.57M | -2.33M | 0 | 5.33M | -333K | -76K | 753K | 2.04M | 6.58M |
| Equity Issued (Net) | 483.07M | 348.33M | 478.66M | 201.26M | 335.87M | 131.2M | 116.1M | 2.4M | 44.53M | 48.56M | 0 | 12.73M | 6.64M | -500K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -285K | -720K |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -173K | -363K | 0 | -500K | 0 |
| Other Financing | 107.75M | 49.54M | -20.92M | 9.41M | -18.63M | -5.93M | -6.22M | 0 | -2.61M | -1.43M | 76K | 50K | 0 | -78 | -50K |
| Net Change in Cash | 4.51M | 112.79M | -3.23M | -52.75M | 113.28M | -3.6M | 21.05M | -7.76M | -14.84M | 25.34M | -7.49M | 5.71M | 4.91M | 96.81K | -538.66K |
| Free Cash Flow | -343.44M | -276.89M | -232.83M | -185.07M | -94.64M | -54.92M | -29.82M | -36.14M | -27.29M | -28.41M | -7.23M | -7.02M | -2.48M | -1.17M | -6.33M |
| FCF Margin % | -1305.42% | -390.81% | -77096.03% | -58938.85% | -5340.58% | -1853.49% | -2840.1% | -810.13% | -325.41% | -709.79% | -216.78% | -276.64% | -57.38% | -27.16% | -143.71% |
| FCF Growth % | -5.24% | -18.92% | -25.81% | -95.56% | -72.32% | -84.16% | 17.48% | -32.43% | 3.96% | -292.77% | -3.03% | -183.22% | -111.42% | 81.48% | - |
| FCF per Share | -3.03 | -3.27 | -3.43 | -4.14 | -2.95 | -4.61 | -8.38 | -17.30 | -13.83 | -22.15 | -10.03 | -13.01 | -16.48 | -6.23 | -34.03 |
| FCF Conversion (FCF/Net Income) | 0.76x | 0.81x | 0.86x | 0.77x | 0.72x | 0.69x | 0.27x | 0.86x | 0.82x | 1.06x | 0.57x | 0.61x | 0.28x | 0.54x | 0.86x |
| Interest Paid | -1.12M | 0 | 1.82M | 0 | 293K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying VRDN stock.
Viridian Therapeutics, Inc. (VRDN) generated $-276.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Viridian Therapeutics, Inc. (VRDN) reported negative free cash flow of $276.9M in 2025, indicating capital requirements exceeded cash from operations.
Viridian Therapeutics, Inc. (VRDN) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Cash runway versus Phase 3 funding
Metrics are mathematically derived from official filings.
Losses Driven by Cash Burn
According to reported quarterly figures, VRDN's operating cash flow tracked its net loss closely, with OCF/NI ratios ranging from 0.71 to 2.45 across the ten quarters, indicating that reported losses are predominantly cash-consumptive rather than accounting-driven.
Because operating cash outflows roughly match net losses, the earnings quality question is less about accruals and more about the absolute size of the burn. Stock-based compensation of $30.4M in 2026Q2 narrows the gap in some quarters but does not change the underlying picture of sustained cash consumption. Investors should monitor whether the ratio stabilizes as R&D spending plateaus, since erratic quarterly swings in conversion appear driven more by working capital timing than by any improvement in cash generation.
Free Cash Flow Deeply Negative Throughout
As reported in financial statements, VRDN's free cash flow margin reached -796.9% in 2026Q2 and -848.8% in 2026Q1, with only modest improvement to -3.6% in 2026Q3 driven largely by lumpy milestone revenue rather than cost discipline.
The margin trajectory is distorted by revenue timing, so the more informative signal is the absolute FCF outflow, which has ranged from roughly $24M to $226M per quarter. The 2026Q3 margin improvement reflects a revenue spike against a relatively stable cash burn, not a structural shift in operating economics. This suggests the company's funding need remains largely independent of milestone receipts, warranting close attention to runway.
Asset-Light Model With Minimal Reinvestment
Based on EDBL's reported figures, VRDN's capital expenditures remained immaterial at under $1.3M in every reported quarter, with CapEx/Revenue ratios swinging widely only because the revenue denominator is erratic.
Negligible capital spending is consistent with a clinical-stage company outsourcing trial execution and manufacturing rather than owning infrastructure. The spikes in CapEx/Revenue, such as 181.8% in 2025Q4, reflect milestone revenue volatility rather than any rise in investment intensity. Because capital needs are minimal, the funding burden sits almost entirely in operating outflows tied to clinical programs.
No Shareholder Returns, All Cash to Trials
As reported in financial statements, VRDN paid no dividends and executed no buybacks or acquisitions across the ten reported quarters, directing all available capital toward operating and clinical activity.
The absence of shareholder distributions is expected for a pre-commercial biotech, and it means every dollar of cash is allocated to funding the THRIVE and THRIVE-2 programs. The company's low leverage, with debt-to-equity of roughly 0.07%, preserves flexibility, but the cash position against quarterly burn of $90M to $225M implies that future equity issuance may be necessary. Investors should weigh the potential for dilution as the primary capital allocation outcome.
Burn Rate Threatens Trial Funding Path
Based on reported figures, VRDN's recent quarterly operating outflows of roughly $90M to $225M, set against a stated cash position near $212M, suggest limited headroom for completing Phase 3 programs without additional capital.
The cash position appears to cover only a small number of quarters at recent burn levels, which may indicate that a financing event is needed before late-stage readouts. Management commentary on Lumvoa's early launch could improve the revenue outlook, but commercial revenue does not yet appear to offset clinical spending. This analysis is an inference from reported figures and warrants further investigation into the company's disclosed runway guidance.